Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients

REAL-B Liver Transplant Study Group

doi:10.1016/j.cgh.2022.01.035

Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients

REAL-B Liver Transplant Study Group

Research output: Contribution to journal › Short survey › peer-review

Original language	English
Pages (from-to)	538-540.e4
Journal	Clinical Gastroenterology and Hepatology
Volume	21
Issue number	2
DOIs	https://doi.org/10.1016/j.cgh.2022.01.035
State	Published - Feb 2023

Access to Document

10.1016/j.cgh.2022.01.035

Cite this

@article{6cffb365de5f47dba5e03ba95696a0c0,

title = "Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients",

author = "{REAL-B Liver Transplant Study Group} and Liu, {Joanne K.} and Philip Vutien and Huang, {Daniel Q.} and Masatoshi Ishigami and Landis, {Charles S.} and Nguyen, {Mindie H.} and Daniel, {Peter Chen Yang Nikhil} and Takanori Ito and Hansen Dang and Mayumi Maeda and Jennifer Leong",

note = "Funding Information: Conflicts of interest These authors disclose the following: Philip Vutien received research support from the National Institutes of Health T32 (DK007742). Daniel Q. Huang received research support from an NMRC Research Training Fellowship (MOH-000595-01); and is on the Advisory board for Eisai. Jennifer Leong received research support from Gilead Sciences. Charles Landis received research support from Pfizer, Gilead Sciences, Eli Lilly, and Hanmi Pharmaceutical. Mindie H. Nguyen received research support from Pfizer, Gilead Sciences, Enanta, Vir Biotech, Glycotests, B. K. Kee Foundation, and the National Cancer Institute; and is on the Advisory board or consultation for Gilead, Intercept, Novartis, Eisai, Bayer, Exact Science, Laboratory of Advanced Medicine, Spring Bank, and Janssen. The remaining authors disclose no conflicts. Funding Information: Conflicts of interest These authors disclose the following: Philip Vutien received research support from the National Institutes of Health T32 (DK007742). Daniel Q. Huang received research support from an NMRC Research Training Fellowship (MOH-000595-01); and is on the Advisory board for Eisai. Jennifer Leong received research support from Gilead Sciences. Charles Landis received research support from Pfizer, Gilead Sciences, Eli Lilly, and Hanmi Pharmaceutical. Mindie H. Nguyen received research support from Pfizer, Gilead Sciences, Enanta, Vir Biotech, Glycotests, B. K. Kee Foundation, and the National Cancer Institute; and is on the Advisory board or consultation for Gilead, Intercept, Novartis, Eisai, Bayer, Exact Science, Laboratory of Advanced Medicine, Spring Bank, and Janssen. The remaining authors disclose no conflicts.",

year = "2023",

month = feb,

doi = "10.1016/j.cgh.2022.01.035",

language = "English",

volume = "21",

pages = "538--540.e4",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients

AU - REAL-B Liver Transplant Study Group

AU - Liu, Joanne K.

AU - Vutien, Philip

AU - Huang, Daniel Q.

AU - Ishigami, Masatoshi

AU - Landis, Charles S.

AU - Nguyen, Mindie H.

AU - Daniel, Peter Chen Yang Nikhil

AU - Ito, Takanori

AU - Dang, Hansen

AU - Maeda, Mayumi

AU - Leong, Jennifer

N1 - Funding Information: Conflicts of interest These authors disclose the following: Philip Vutien received research support from the National Institutes of Health T32 (DK007742). Daniel Q. Huang received research support from an NMRC Research Training Fellowship (MOH-000595-01); and is on the Advisory board for Eisai. Jennifer Leong received research support from Gilead Sciences. Charles Landis received research support from Pfizer, Gilead Sciences, Eli Lilly, and Hanmi Pharmaceutical. Mindie H. Nguyen received research support from Pfizer, Gilead Sciences, Enanta, Vir Biotech, Glycotests, B. K. Kee Foundation, and the National Cancer Institute; and is on the Advisory board or consultation for Gilead, Intercept, Novartis, Eisai, Bayer, Exact Science, Laboratory of Advanced Medicine, Spring Bank, and Janssen. The remaining authors disclose no conflicts. Funding Information: Conflicts of interest These authors disclose the following: Philip Vutien received research support from the National Institutes of Health T32 (DK007742). Daniel Q. Huang received research support from an NMRC Research Training Fellowship (MOH-000595-01); and is on the Advisory board for Eisai. Jennifer Leong received research support from Gilead Sciences. Charles Landis received research support from Pfizer, Gilead Sciences, Eli Lilly, and Hanmi Pharmaceutical. Mindie H. Nguyen received research support from Pfizer, Gilead Sciences, Enanta, Vir Biotech, Glycotests, B. K. Kee Foundation, and the National Cancer Institute; and is on the Advisory board or consultation for Gilead, Intercept, Novartis, Eisai, Bayer, Exact Science, Laboratory of Advanced Medicine, Spring Bank, and Janssen. The remaining authors disclose no conflicts.

PY - 2023/2

Y1 - 2023/2

UR - http://www.scopus.com/inward/record.url?scp=85126536479&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2022.01.035

DO - 10.1016/j.cgh.2022.01.035

M3 - Short survey

C2 - 35123081

AN - SCOPUS:85126536479

SN - 1542-3565

VL - 21

SP - 538-540.e4

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 2

ER -